•  Summary 
  •  
  •  Actions 
  •  
  •  Committee Votes 
  •  
  •  Floor Votes 
  •  
  •  Memo 
  •  
  •  Text 
  •  
  •  LFIN 
  •  
  •  Chamber Video/Transcript 

S00621 Summary:

BILL NOS00621
 
SAME ASSAME AS A02202
 
SPONSORLIU
 
COSPNSROBERACKER, SCARCELLA-SPANTON
 
MLTSPNSR
 
Amd §7101-a, Ed L
 
Amends the definitions of diagnostic pharmaceuticals, topical therapeutic pharmaceutical agents, and therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension as they relate to the certification to use therapeutic drugs in the practice of optometry.
Go to top

S00621 Text:



 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                           621
 
                               2025-2026 Regular Sessions
 
                    IN SENATE
 
                                       (Prefiled)
 
                                     January 8, 2025
                                       ___________
 
        Introduced  by  Sen.  LIU  --  read  twice and ordered printed, and when
          printed to be committed to the Committee on Higher Education
 
        AN ACT to amend the education law, in relation to  the  use  of  topical
          pharmaceutical agents

          The  People of the State of New York, represented in Senate and Assem-
        bly, do enact as follows:
 
     1    Section 1.  Paragraphs (d), (e) and (f) of subdivision  1  of  section
     2  7101-a  of  the  education law, paragraph (d) as added by chapter 517 of
     3  the laws of 1995 and paragraphs (e) and (f) as amended by chapter 506 of
     4  the laws of 2021, are amended to read as follows:
     5    (d) Diagnostic pharmaceuticals. Diagnostic pharmaceuticals shall  mean
     6  those  drugs  which  shall  be  limited  to topical applications [to the
     7  surface of the eye] for the purpose of diagnostic examination of the eye
     8  [and shall be limited to:
     9    (i) Anesthetic agents;
    10    (ii) Mydriatics;
    11    (iii) Cycloplegics;
    12    (iv) Miotics;
    13    (v) Disclosing agents and other substances used  in  conjunction  with
    14  these drugs as part of a diagnostic procedure] and adnexa.
    15    (e)  Topical  therapeutic  pharmaceutical  agents. Topical therapeutic
    16  pharmaceutical agents shall mean those drugs which shall be  limited  to
    17  topical application [to the surface of the eye] for therapeutic purposes
    18  [and shall be limited to:
    19    (i) antibiotic/antimicrobials;
    20    (ii) decongestants/anti-allergenics;
    21    (iii) non-steroidal anti-inflammatory agents;
    22    (iv) steroidal anti-inflammatory agents;
    23    (v) antiviral agents;
    24    (vi) hyperosmotic/hypertonic agents;

         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD02383-01-5

        S. 621                              2

     1    (vii) cycloplegics;
     2    (viii) artificial tears and lubricants; and
     3    (ix) immunosuppressive agents] of the eye and adnexa.
     4    (f)  Therapeutic  pharmaceutical  agents for treatment of glaucoma and
     5  ocular hypertension. Therapeutic pharmaceutical agents for treatment  of
     6  glaucoma  and  ocular hypertension shall mean those drugs which shall be
     7  limited to topical application [to the surface] for therapeutic purposes
     8  of the eye and [shall be limited to:
     9    (i) beta blockers;
    10    (ii) alpha agonists;
    11    (iii) direct acting cholinergic agents;
    12    (iv) prostaglandin analogs; and
    13    (v) carbonic anhydrase inhibitors] adnexa.
    14    § 2. Paragraph (e) of subdivision 4 of section 7101-a of the education
    15  law, as added by chapter 517 of the laws of 1995 and  as  relettered  by
    16  chapter 506 of the laws of 2021, is amended to read as follows:
    17    (e) The provisions of paragraphs (a) and (b) of this subdivision shall
    18  not  apply  to  (i)  graduates of an appropriate program approved by the
    19  department who have successfully passed the examination on  the  use  of
    20  diagnostic  and  therapeutic [drugs] agents and who graduated subsequent
    21  to January first, nineteen hundred ninety-three;  or  (ii)  optometrists
    22  who  have  been  certified  for  at  least five years to use [phase one]
    23  topical therapeutic agents and [phase two drugs] therapeutic  pharmaceu-
    24  tical agents for treatment of glaucoma and ocular hypertension in anoth-
    25  er  jurisdiction,  have  demonstrated  such use in independently managed
    26  patients, and have been licensed in accordance with section  seventy-one
    27  hundred  four  of this chapter. Provided, however, no optometrist exempt
    28  under this paragraph shall be permitted to use [phase one] topical ther-
    29  apeutic pharmaceutical agents or [phase two] therapeutic  pharmaceutical
    30  agents  for  treatment  of glaucoma and ocular hypertension prior to the
    31  general authorization provided to optometrists licensed in this state.
    32    § 3. The opening paragraph of  paragraph  (b)  and  paragraph  (c)  of
    33  subdivision  10  of  section  7101-a of the education law, as amended by
    34  chapter 506 of the laws of 2021, are amended to read as follows:
    35    Those optometrists having been certified for topical therapeutic phar-
    36  maceutical agents shall be authorized to use and prescribe  all  topical
    37  therapeutic  pharmaceutical agents [specified in paragraph (e) of subdi-
    38  vision one of this section], which are  FDA  approved  and  commercially
    39  available for topical use.
    40    (c)  Those  optometrists having been certified for therapeutic pharma-
    41  ceutical agents for treatment of glaucoma and ocular hypertension  shall
    42  be authorized to use and prescribe therapeutic pharmaceutical agents for
    43  treatment  of  glaucoma  and ocular hypertension [specified in paragraph
    44  (f) of subdivision one of this section],  which  are  FDA  approved  and
    45  commercially available.
    46    § 4. This act shall take effect immediately.
Go to top